Patient | BASDAI week 0 Mean: 5.5 Median: 5.2 | BASDAI week 24 Mean: 1.9 Median: 1.8 | ESR week 0 Mean: 43 Median: 26.5 | ESR week 24 Mean: 11 Median: 8.5 | CRP week 0 Mean: 52 Median: 25 | CRP week 24 Mean: 8 Median: 5 | ASAS 20% | Infliximab level (ng/ml) | ATI (ng/ml) |
---|---|---|---|---|---|---|---|---|---|
ASA, acetylsalicylic acid; ASAS, assessment in ankylosing spondylitis; ATI, antibodies to infliximab; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate. | |||||||||
BASDAI score (scale 0–10), ESR (mm/h), CRP (mg/l), ASAS 20% response. | |||||||||
*Considered as non-responders owing to increase in inflammatory parameters. | |||||||||
†Not done owing to severe visual impairment. | |||||||||
1 | 6.4 | 1.2 | 88 | 4 | 115 | 4 | + | 17 800 | 0 |
2 | 4.5 | 0.7 | 90 | 8 | 120 | 6 | + | 10 100 | 0 |
3* | † | † | 22 | 26 | 14 | 21 | † | 0 | 7200 |
4 | 7.2 | 0.0 | 72 | 18 | 104 | 6 | + | 20 600 | 0 |
5* | 4.7 | 3.1 | 12 | 18 | 7 | 20 | + | 0 | 15 600 |
6 | 4.5 | 1.8 | 23 | 9 | 11 | <2.5 | + | 16 000 | 0 |
7 | 5.2 | 4.1 | 10 | 6 | 7 | <2.5 | + | 10 300 | 0 |
8 | 6.3 | 2.1 | 30 | 1 | 36 | <2.5 | + | 16 400 | 0 |